SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 1,799 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 1,799 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total value of $23,297.05. Following the completion of the sale, the senior vice president owned 284,175 shares of the company’s stock, valued at $3,680,066.25. The trade was a 0.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

SiBone Stock Performance

Shares of SIBN stock opened at $13.12 on Friday. SiBone has a 1-year low of $12.15 and a 1-year high of $21.89. The company has a current ratio of 8.55, a quick ratio of 7.21 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $579.51 million, a price-to-earnings ratio of -29.82 and a beta of 0.77. The stock’s fifty day simple moving average is $14.62 and its 200-day simple moving average is $16.37.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.09. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%.The firm had revenue of $56.35 million during the quarter, compared to the consensus estimate of $56.26 million. On average, sell-side analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on SIBN. Needham & Company LLC raised their price target on shares of SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Wall Street Zen upgraded shares of SiBone from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Truist Financial reiterated a “buy” rating and issued a $24.00 target price (up from $23.00) on shares of SiBone in a research report on Tuesday, February 24th. TD Cowen lifted their target price on shares of SiBone from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Institutional Investors Weigh In On SiBone

A number of large investors have recently bought and sold shares of SIBN. Royal Bank of Canada increased its position in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of SiBone by 0.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 225,001 shares of the company’s stock worth $4,437,000 after buying an additional 997 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after buying an additional 1,053 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of SiBone by 42.3% during the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after acquiring an additional 1,061 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after acquiring an additional 1,459 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.